Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Frank M, Speetjens"'
Autor:
Hans Gelderblom, Marta Fiocco, Simon P Mooijaart, Gerrit-Jan Liefers, Wilbert B van den Hout, Frank M Speetjens, Frederiek van den Bos, Leti van Bodegom-Vos, Marije Slingerland, Nienke A de Glas, Johanneke E A Portielje, Marissa Cloos-van Balen, Joosje C Baltussen, Trishika R R Binda, Arjan J Verschoor, Cynthia Holterhues, Danny Houtsma, Anouk Jochems, Leontine E A M M Spierings
Publikováno v:
BMJ Open, Vol 14, Iss 8 (2024)
Introduction Treating older adults with chemotherapy remains a challenge, given their under-representation in clinical trials and the lack of robust treatment guidelines for this population. Moreover, older patients, especially those with frailty, ha
Externí odkaz:
https://doaj.org/article/cc10accdfbcd4ad6ba94b0ed10167cff
Autor:
Julius C. Heemelaar, Jeroen Janson, Jerry Braun, Frank M. Speetjens, Michiel A. J. van de Sande, Juan D. V. Hugo, Daniela Q. C. M. Barge-Schaapveld, Saskia L. M. A. Beeres, Laurens F. Tops, Hans Gelderblom, M. Louisa Antoni
Publikováno v:
Cardio-Oncology, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are one of the corner stones of osteosarcoma treatment, and therefore several guidelines are in
Externí odkaz:
https://doaj.org/article/5f7e209b055645dbbcbf6947d9e15655
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-9 (2022)
Abstract Background and purpose To gain insight into the treatment outcomes for anal cancer a retrospective analysis was performed with a special emphasis on trends in outcome and toxicities over time and on treatment of elderly patients. Materials a
Externí odkaz:
https://doaj.org/article/46424a07b680469bb3c45db7397d65ca
Autor:
Hans Gelderblom, Sjoerd H van der Burg, Ferry Ossendorp, Peggy J de Vos van Steenwijk, Mariette I E van Poelgeest, Inge Roozen, Willem-Jan Krebber, Cornelis J M Melief, Frank M Speetjens, Marij J P Welters, Nikki M Loof, Sanne Boekestijn, Catharina A H Janssen, Marije Slingerland, Gijs G Zom, A Rob P M Valentijn, Nico J Meeuwenoord, Gijs A van der Marel, Dmitri V Filippov
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Amplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen presentation
Externí odkaz:
https://doaj.org/article/116d0102ba984134b3b45409c8b1b84b
Autor:
Julius C. Heemelaar, Frank M. Speetjens, Ahmed A.M. al Jaff, Richard E. Evenhuis, Elissa A.S. Polomski, Bart J.A. Mertens, J. Wouter Jukema, Hans Gelderblom, Michiel A.J. van de Sande, M. Louisa Antoni
Publikováno v:
JACC: CardioOncology. 5:117-127
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aa38450f8460e25400634a956fd8e6e
https://doi.org/10.1016/j.jaccao.2022.11.016
https://doi.org/10.1016/j.jaccao.2022.11.016
Autor:
H. S. Femke Hagenmaier, Annelies G. K. van Beeck, Rick L. Haas, Veroniek M. van Praag, Leti van Bodegom-Vos, Jos A. van der Hage, Stijn Krol, Frank M. Speetjens, Arjen H. G. Cleven, Ana Navas, Herman M. Kroon, Rieneke G. Moeri-Schimmel, Nicolette A. C. Leyerzapf, Michiel A. J. van de Sande
Publikováno v:
Sarcoma, Vol 2021 (2021)
Background. With soft-tissue sarcoma of the extremity (ESTS) representing a heterogenous group of tumors, management decisions are often made in multidisciplinary team (MDT) meetings. To optimize outcome, nomograms are more commonly used to guide ind
Externí odkaz:
https://doaj.org/article/5d1a901457534028844ef4ccfcca2cb2
Autor:
Gerrit-Jan Liefers, Sjoerd H van der Burg, Monique K van der Kooij, Marten Visser, Linda de Bruin, Ellen Kapiteijn, Els M E Verdegaal, Caroline E van der Minne, Pauline M Meij, Inge C F M Roozen, Mare A Jonker, Shelley van den Bosch, Frank M Speetjens
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Introduction Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltratin
Externí odkaz:
https://doaj.org/article/7801791fed264d05be8148157a140694
Autor:
Frank M. Speetjens, Rick L. Haas, Rieneke G. Moeri-Schimmel, Annelies G. K. van Beeck, Stijn Krol, Michiel A. J. van de Sande, Veroniek M. van Praag, Arjen H.G. Cleven, Herman M. Kroon, Jos A. van der Hage, Ana Navas, Nicolette A. C. Leyerzapf, H. S. Femke Hagenmaier, Leti van Bodegom-Vos
Publikováno v:
Sarcoma
Sarcoma, Vol 2021 (2021)
Sarcoma, Vol 2021 (2021)
Background. With soft-tissue sarcoma of the extremity (ESTS) representing a heterogenous group of tumors, management decisions are often made in multidisciplinary team (MDT) meetings. To optimize outcome, nomograms are more commonly used to guide ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2330e346f9d302d7560190459136a1a3
https://doi.org/10.1155/2021/8851354
https://doi.org/10.1155/2021/8851354
Autor:
Thaïs M.L. Tong, Frank M. Speetjens, Monique K van der Kooij, C. Blank, Rutger W. van der Meer, Jacob Lutjeboer, Els L. van Persijn van Meerten, Arian R. van Erkel, Fred G.J. Tijl, Ellen Kapiteijn, Remco W. M. Zoethout, Chris H. Martini, Mark C. Burgmans
Background: While immune checkpoint inhibition (ICI) has revolutionized the treatment of metastatic cutaneous melanoma, no standard treatments are available for patients with metastatic uveal melanoma (UM). Several locoregional therapies are effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bf6e94d3b2d0648a130904fa30455a3
https://doi.org/10.21203/rs.3.rs-592047/v1
https://doi.org/10.21203/rs.3.rs-592047/v1
Autor:
Hans Gelderblom, Judith V.M.G. Bovée, Arie J. Verschoor, Michiel A. J. van de Sande, Marta Fiocco, Frank M. Speetjens, P. D. Sander Dijkstra
Publikováno v:
Oncologist
The Oncologist
The Oncologist
Background The effectiveness of second‐line palliative chemotherapy in patients with recurrent/metastatic osteosarcoma is not well defined. Several small studies (6–19 patients) have reported on ifosfamide as second‐line treatment. In this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3a276b6a2d62d7c4074fbc5b1c9a66e
https://doi.org/10.1634/theoncologist.2019-0528
https://doi.org/10.1634/theoncologist.2019-0528